Elan Shares Climb on $3.25B Biogen's Tysabri Deal

Feb. 6 (Bloomberg) -- Bloomberg's Caroline Hyde reports on what is next for Elan Corp. as Biogen Idec Inc. agreed to acquire the company's stake in the multiple sclerosis drug Tysabri for $3.25 billion in cash plus future royalties. She speaks on Bloomberg Television's "The Pulse."
How Emerging Markets Will Rebalance
31:06 - BlackRock Emerging Markets senior strategist Pablo Goldberg discusses charting the emerging market supercycle with Bloomberg's Scarlet Fu, Joe Weisenthal and Alix Steel on "What'd You Miss?" (Source: Bloomberg)
  • Intel’s Sales Mean Strong Data-Center Chip Demand
  • JPMorgan 3Q Profit Increases 22% on Tax Benefits
  • JPMorgan: Results 'Decent' This Quarter